Browsing by Author "Price, K"
Now showing items 1-5 of 5
-
Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin
Amin, Alpesh; Keshishian, A; Xie, L; Başer, Onur; Price, K; Vo, L; Singh, P; Bruno, A; Mardekian, J; Tan, W; Singhal, S; Patel, C; Odell, K; Trocio J. (2015)... -
Comparison of short term bleeding-related health care utilization and costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivoxaban or warfarin
Keshishian, A; Xie, L; Başer, Onur; Price, K; Vo, L; Singh, P; Bruno, A; Mardekian, J; Tan, W; Singha, S; Patel C; Odell, K; Trocio J. (2015)... -
Early comparison of major bleeding, stroke and associated medical costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban or warfarin
Alpesh, A; Keshishian, A; Xie, L; Başer, Onur; Price, K; Vo, L; Singh, P; Bruno, A; Mardekian, J; Tan, W; Singhal, S; Patel, C; Odell, K; Trocio J. (2015)... -
Real-world comparison of major bleeding and associated costs among treatment-naïve nonvalvular atrial fibrillation patients initiating apixaban or warfarin
Amin, Alpesh; Keshishian, A; Xie L; Başer, Onur; Price, K; Vo, L; Mardekian, J; Mendoza, M; Singhal, S; Patel, C; Odell, K; Trocio, J (2016)... -
Real-world comparison of major bleeding risk among untreated non-valvular atrial fibrillation patients and those initiating apixaban, dabigatran, rivaroxaban, or warfarin
Amin, Alpesh; Keshishian, A; Xie, L; Başer, Onur; Price, K; Vo, L; Mardekian, J; Mendoza, M; Singhal, S; Patel, C; Odell, K; Trocio J. (2016)Background: Recent large randomized controlled trials have shown that novel oral anticoagulants (NOACs) are at least as effective as warfarin for risk reduction of stroke in patients with non-valvular atrial fibrillation ...
